Searched for: subject%3A%22Hyperlipoproteinemia%255C%2BType%255C%2BIII%22
(1 - 10 of 10)
document
Post, S.M. (author), Groenendijk, M. (author), Solaas, K. (author), Rensen, P.C.N. (author), Princen, H.M.G. (author), TNO Preventie en Gezondheid (author)
Objective-Cholesterol 7α-hydroxylase (cyp7a1) catalyzes the rate-limiting step in conversion of cholesterol to bile acids. To study the relationship between bile acid biosynthesis and triglyceride metabolism, we cross-bred mice lacking cyp7a1 on a hyperlipidemic APOE*3-Leiden background. Methods and Results-Female mice received a chow or...
article 2004
document
de Beer, F. (author), Stalenhoef, A.F.H. (author), Hoogerbrugge, N. (author), Kastelein, J.J.P. (author), Leuven, J.A.G. (author), van Duijn, C.M. (author), Havekes, L.M. (author), Smelt, A.H.M. (author), Gaubius Instituut TNO (author)
Type III hyperlipoproteinemia (HLP) is mainly found in homozygous carriers of apolipoprotein E2 (apoE2, Arg158→Cys). Only a small percentage (<5%) of these apoE2 homozygotes develops hyperlipidemia, indicating that additional environmental and genetic factors contribute to the expression of type III HLP. In the present study, first, the...
article 2002
document
de Beer, F. (author), van Dijk, K.W. (author), Jong, M.C. (author), van Vark, L.C. (author), van der Zee, A. (author), Hofker, M.H. (author), Fallaux, F.J. (author), Hoeben, R.C. (author), Smelt, A.H.M. (author), Havekes, L.M. (author), Gaubius Instituut TNO (author)
The apolipoprotein E2 (Lys146→Gln) variant is associated with a dominant form of familial dysbetalipoproteinemia. Heterozygous carriers of this variant have elevated levels of plasma triglycerides, cholesterol, and apolipoprotein E (apoE). It was hypothesized that the high amounts of triglycerides in the very low density lipoprotein (VLDL)...
article 2000
document
Sijbrands, E.J.G. (author), Hoffer, M.J.V. (author), Meinders, A.E. (author), Havekes, L.M. (author), Frants, R.R. (author), Smelt, A.H.M. (author), de Knijff, P. (author), Gaubius instituut TNO (author)
More than 90% of patients with type III hyperlipoproteinemia are homozygous carriers of the apolipoprotein (apo) E*2 allele. The great majority of these apoE2(Arg158→Cys) homozygotes in the general population, however, are normolipidemic. Apparently, expression of the hyperlipidemic state requires additional genetic and/or environmental factors,...
article 1999
document
de Man, F.H.A.F. (author), de Beer, F. (author), van der Laarse, A. (author), Smelt, A.H.M. (author), Leuven, J.A.G. (author), Havekes, L.M. (author), Gaubius Instituut TNO (author)
Lipoprotein lipase (LPL) is bound to heparan sulphate proteoglycans (HSPG) at the luminal surface of endothelium. It is the key enzyme involved in the hydrolysis of very low density lipoproteins (VLDL). Prior to lipolysis by LPL, the lipoproteins are considered to interact with vessel wall HSPG. Apolipoprotein (apo) E is thought to mediate this...
article 1998
document
Hoffer, M.J.V. (author), Niththyananthan, S. (author), Naoumova, R.P. (author), Kibirige, M.S. (author), Frants, R.R. (author), Havekes, L.M. (author), Thompson, G.R. (author), Gaubius Instituut TNO (author)
Apolipoprotein E (apoE) is one of the major protein constituents of chylomicron and very low density lipoprotein (VLDL) remnants and plays a central role as a ligand in the receptor-mediated uptake of these particles by the liver. Here we describe a new variant of apoE, apoE1-Hammersmith, which is associated with dominantly expressed type III...
article 1996
document
de Knijff, P. (author), van den Maagdenberg, A.M.J.M. (author), Frants, R.R. (author), Havekes, L.M. (author), TNO Preventie en Gezondheid (author)
Apolipoprotein E (apoE) is one of the major protein constituents of chylomicron and very-low-density lipoprotein (VLDL) remnants and plays a central role as a ligand in the receptor-mediated uptake of these particles by the liver. Including the most common variant, apoE3, 30 apoE variants have been characterized. At present, 14 apoE variants...
article 1994
document
TNO Preventie en Gezondheid (author), Mulder, M. (author), van der Boom, H. (author), de Knijff, P. (author), Braam, C. (author), van den Maagdenberg, A. (author), Gevers Leuven, J.A. (author), Havekes, L.M. (author)
The APOE*2(Lys146 → Gln) allele behaves like a dominant trait in the expression of familial dysbetalipoproteinemia (FD) (Smit et al., J. Lipid Res. 1990; 31: 45-53). FD patients carrying the APOE*2(Lys146 → Gln) allele exhibit less elevated cholesterol to triglyceride ratios in the d < 1.019 g/ml lipoprotein density fraction as compared to...
article 1994
document
Gaubius Instituut TNO (author), de Knijff, P. (author), van den Maagdenberg, A.M.J.M. (author), Stalenhoef, A.F.H. (author), Leuven, J.A.G. (author), Demacker, P.N.M. (author), Kuyt, L.P. (author), Frants, R.R. (author), Havekes, L.M. (author)
By the careful screening of familial dysbetalipoproteinemic (FD) patients, five probands showing heterozygosity for the APOE*3-Leiden allele were found. Genealogical studies revealed that these probands share common ancestry in the 17th century. In a group of 128 family members, spanning three generations, 37 additional heterozygous APOE*3...
article 1991
document
Gaubius instituut TNO (author), Havekes, L.M. (author), de Knijff, P. (author), Beisiegel, U. (author), Havinga, J. (author), Smit, M. (author), Klasen, E. (author)
A new method for the apolipoprotein E phenotyping has been developed. The method is based on isoelectric focusing of either delipidated or guanidine-HCl-treated serum or plasma in a horizontal slab gel system followed by immunoblotting using either polyclonal or monoclonal anti-apolipoprotein E antibodies as first antibody. Apolipoprotein E...
article 1987
Searched for: subject%3A%22Hyperlipoproteinemia%255C%2BType%255C%2BIII%22
(1 - 10 of 10)